Aspen Neuroscience prices $141M IPO to advance autologous Parkinson's cell therapy into later-stage trials
- Aspen sold about 9.4 million shares at $15, the low end of its marketed range, raising roughly $140.6M; shares trade as ASPE from Friday.
- Lead candidate sasineprocel is a one-time therapy made from a patient's own skin cells, converted to stem cells and then dopamine-producing neurons.
- An open-label Phase 1/2a study showed early 12-month functional gains and a favorable safety profile; a Phase 3 is planned to start by end of next year.
💡 Points Based on public reports
Pricing at the low end of the range, $141M buys Aspen roughly one Phase 3, not a platform. Autologous iPSC is its differentiator against Bayer's BlueRock allogeneic rival, but also its cost and manufacturing-turnaround burden. Open-label, early functional gains are soft; the Phase 3 design and control arm will decide credibility.
Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson's ↗